医药生物行业周报 药辅行业迈入成熟期，关注医药辅料优 势企业 2026 年 03 月 02 日 【行情回顾】 【本周观点】 【风险提示】 医药行业政策风险；研发进展不及预期风险；业绩不及预期风险 挖掘价值 投资成长 强于大市（维持） 东方财富证券研究所 证券分析师：何玮 证书编号：S1160517110001 证券分析师：崔晓倩 证书编号：S1160525080001 相对指数表现 -10% -2% 6% 14% 22% 30% 2025/3 2025/9 2026/3 医药生物 沪深300 相关研究 《"小而美"药辅行业迎来产业升级》 2026.02.24 《ADC 商业化进程提速，本土创新药企多 路径布局产能》 2026.02.09 《《药品管理法实施条例》全面修订，推动 医药产业创新与监管升级》 2026.02.03 《医药零售高质量发展政策发布，行业有 望加速整合利好龙头》 2026.01.27 《J.P. Morgan 健康大会召开，中国创新药 企扬帆出海》 2026.01.20 行 业 研 究 / 医 药 生 物 / 证 券 研 究 报 告 本周(2026/02/23-2026/02/27，下同） ...

山东赫达 20260227 摘要 2026 年 1-2 月，公司纤维素与植物胶囊销量创历史新高，植物胶囊直 接交付终端客户量达单月 28 亿粒，较 2025 年月均水平提升 1.1-1.5 倍， 实际发货量更高，显示强劲增长势头。 美国建厂决策获客户积极响应，现有客户承诺增加采购，潜在客户表示 将开展合作，部分客户已开始从美国工厂相关主体拿货，验证了客户承 诺的真实性与持续性。 美国市场竞争格局变化显著，主要竞争对手罗克特计划于 2026 年末关 闭美国工厂，龙沙拟剥离全球胶囊业务，为公司在美国市场份额提升提 供重要机会。 为配合美国工厂投产，国内工厂自 2025 年四季度起加班生产，恢复部 分停置设备，有效产能已恢复至 300 亿粒以上，春节期间亦未停工，旨 在抢占市场份额。 欧洲市场延续快速增长，2025 年销量达 70 多亿粒，预计 2026 年突破 100 亿粒，甚至可能达到 110-120 亿粒，其他海外市场亦呈现增长态 势，国内产能将主要服务欧洲市场。 Q&A 在 2025 年年报尚未披露的前提下，2025 年整体经营情况与 2024 年相比有 哪些可量化的变化？ 2025 年在外部环境极其恶劣的 ...

医药生物行业专题研究 "小而美"药辅行业迎来产业升级 2026 年 02 月 24 日 【投资要点】 【配置建议】 建议关注医药辅料优势企业山河药辅等；植物胶囊优势企业山东赫达 等。 【风险提示】 挖掘价值 投资成长 强于大市（维持） 东方财富证券研究所 证券分析师：何玮 证书编号：S1160517110001 相对指数表现 -10% -2% 6% 14% 22% 30% 2025/2 2025/8 2026/2 医药生物 沪深300 相关研究 《ADC 商业化进程提速，本土创新药企多 路径布局产能》 2026.02.09 《《药品管理法实施条例》全面修订，推动 医药产业创新与监管升级》 政策落地执行不达预期； 药用辅料国产替代延迟； 新型高端辅料推进不达预期； 消费降级保健品增长不达预期； 2026.02.03 《医药零售高质量发展政策发布，行业有 望加速整合利好龙头》 2026.01.27 《J.P. Morgan 健康大会召开，中国创新药 企扬帆出海》 2026.01.20 《聚焦脑机接口与小核酸药物，JPM 盛会 前奏下医疗布局新浪潮》 2026.01.14 行 业 研 究 / 医 药 生 物 / 证 ...

Group 1: Lier Chemical - Lier Chemical is a global leader in chlorinated pyridine herbicides and a leading company in glyphosate and refined glyphosate, with products sold in over 30 countries and regions [1] - The core growth logic is driven by the accelerated ban on glyphosate, with the market size for glyphosate expected to grow from 3 billion yuan in 2020 to 8 billion yuan in 2025, representing a compound annual growth rate (CAGR) of 22% [1] - Lier Chemical is the second company globally and the first in China to master the industrialization of cyanopyridine chlorination technology, with a total production capacity exceeding 50,000 tons per year, achieving full production and sales [1] - The company has a market share of over 70% globally, with more than 80% of its sales coming from long-term supply agreements, and both product categories are currently in a price increase cycle [1] - The company has seen its performance improve by over 100% for three consecutive quarters [1] Group 2: Shandong Heda - Shandong Heda is the absolute leader in cellulose ether in China and a core supplier of plant capsules globally, with raw materials sourced from cotton, wood, and bamboo [2] - The focus is on medical-grade and food-grade cellulose ether, with profit margins reaching 25% to over 35%, particularly for medical-grade cellulose ether, which sees annual price increases and growing margins [2] - The company has established long-term supply agreements with major domestic pharmaceutical companies such as Heng Rui and Shi Yao, as well as international firms like Pfizer, Novartis, and Bayer, supplying 15 out of the top 20 global pharmaceutical companies [2] - The global capsule market is over 30 billion yuan, with the share of plant capsules expected to increase from 15% in 2020 to 30% in 2025, reflecting a CAGR of over 20% as a clear trend to replace gelatin capsules [2] - Shandong Heda has a domestic production capacity of 20 billion capsules per year, with a $500 million investment in the U.S. to build a project with the same capacity, expected to be operational by Q3 2026 [2]

Core Viewpoint - The company, Shenqi Pharmaceutical, reported that its subsidiary, Guizhou Guangdeli Pharmaceutical Co., Ltd., primarily produces gelatin hollow capsules and plant-based capsules, with some products sold in the EU market [1] Group 1: Company Performance - As of the third quarter of 2025, the subsidiary's revenue reached 53.1371 million yuan, accounting for 3.8% of Shenqi Pharmaceutical's total revenue [1]

Summary of Shandong Heda's Conference Call Company Overview - **Company**: Shandong Heda - **Industry**: Plant-based capsules Key Points and Arguments Impact of US Anti-Dumping Duties - The US government has decided to refund the deposits, significantly alleviating the performance pressure on Shandong Heda. Previously, the prices of products exported to the US had fallen below cost, severely impacting Q3 performance. This ruling is crucial for improving current and future performance [2][3] - The company has been granted an extended window period from November 28, 2025, to February 2, 2026, during which capsules sold to the US will be exempt from anti-dumping deposits, providing a unique opportunity to accelerate shipments to the US [2][3] Competitive Tax Rate - The comprehensive tax rate for Shandong Heda's Shumei capsules is 55.81%, which is lower than competitors from India (79.47%), Brazil (71.96%), and Vietnam (71.39%). This competitive edge is expected to enhance market competitiveness after the US production capacity comes online [2][3][4] Future Production and Market Demand - The US plant is expected to start production in the second half of 2026, which will significantly boost the profitability of the plant-based capsule business. New product development is also anticipated to increase revenue. The demand for plant-based capsules in the US is projected to approach 100 billion capsules over the next three years [2][5] - The company aims to achieve full capacity operation within three to five years, targeting to surpass Lonza and become the global leader in the plant-based capsule sector [7][8] Domestic Capacity Management - To address domestic capacity issues, the company is implementing various measures, including phasing out outdated equipment, improving production efficiency, and increasing efforts in the European market. The goal for European sales is set to grow by 45%-50% year-on-year [6] Market Pricing and Profitability - The price of plant-based capsules in the US has risen to $300-$330 per 10,000 capsules in 2025, a 20% increase from the previous year. The company expects that with new production capacity, the cost per 10,000 capsules will be controlled around 140 RMB, leading to a gross profit of 150 RMB, significantly enhancing profitability [3][11][12] Industry Dynamics - The global demand for plant-based capsules is approximately 150 billion capsules, with the US accounting for 60% and Europe for 30%. The company will continue to focus on the US and European markets, which are expected to remain dominant in the short term [13] - The competitive landscape includes around 70 new plant-based capsule companies in China, with a total capacity of about 800 billion capsules, but only 50%-60% of this capacity is effectively shipped. This oversupply has led to price and margin pressures [14] Financial Performance and Projections - The gross margin for Shandong Heda has dropped to 6-7% in Q3 2025, but the company anticipates a market correction by late 2026, with many excess capacities exiting the market. A return to breakeven or slight profitability is expected [17] - In Q4, expenses are typically concentrated, leading to a higher expense ratio. However, due to better-than-expected performance in the first three quarters, the overall annual performance remains acceptable [18] Anti-Dumping Tax Adjustments - The anti-dumping tax rate for Shandong Heda has been reduced from 172% to 18%, aligning more closely with other Chinese companies. This adjustment has significantly improved profit margins for exports to the US [19][20] Price Recovery - Prior to the anti-dumping measures, the selling price to the US was approximately 220 RMB per 10,000 capsules, which fell to about 1.1 USD (approximately 77 RMB) recently. Prices have since recovered to over 200 RMB [21]

Company Information - Shandong Heda announced that its director and vice general manager, Bi Songling, plans to reduce his shareholding by up to 350,000 shares, which represents 0.1017% of the company's total share capital, within three months after 15 trading days from the announcement date [1] - As of the report, Shandong Heda has a market capitalization of 4.6 billion yuan [1] Revenue Composition - For the first half of 2025, Shandong Heda's revenue composition is as follows: cellulose ether accounts for 72.98%, plant capsules account for 21.1%, other trade chemical products account for 3.86%, graphite chemical equipment accounts for 1.9%, and other businesses account for 0.16% [1]

Company Summary - Shandong Heda announced a share buyback plan, repurchasing approximately 2.43 million shares, which accounts for 0.6973% of the total share capital, with a total expenditure of about 29.93 million yuan [1] - The highest transaction price during the buyback was approximately 14.29 yuan per share, while the lowest was 11.1 yuan per share [1] - As of the report date, Shandong Heda's market capitalization stands at 4.6 billion yuan [1] Revenue Composition - For the first half of 2025, Shandong Heda's revenue composition is as follows: cellulose ether accounts for 72.98%, plant capsules for 21.1%, other trade chemical products for 3.86%, graphite chemical equipment for 1.9%, and other businesses for 0.16% [1]

Company Overview - Huangshan Capsule Co., Ltd. is located in Anhui Province and was established on August 12, 1996, with its listing date on October 25, 2016 [2] - The company specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules [2] - The revenue composition includes gelatin hollow capsules (64.54%), enteric-coated gelatin hollow capsules (19.22%), and plant capsules and others (16.24%) [2] Stock Performance - As of September 23, the stock price of Huangshan Capsule decreased by 2.01% to 7.32 CNY per share, with a total market capitalization of 2.189 billion CNY [1] - Year-to-date, the stock price has increased by 18.16%, but it has seen a decline of 5.91% over the last five trading days, 9.85% over the last 20 days, and 1.88% over the last 60 days [2] Financial Performance - For the period from January to June 2025, Huangshan Capsule achieved a revenue of 244 million CNY, representing a year-on-year growth of 3.66% [2] - The net profit attributable to the parent company was 35.55 million CNY, showing a year-on-year increase of 19.78% [2] Shareholder Information - As of June 30, 2025, the number of shareholders was 17,900, a decrease of 2.57% from the previous period [2] - The average circulating shares per person increased by 2.64% to 16,197 shares [2] - The company has distributed a total of 125 million CNY in dividends since its A-share listing, with 62.81 million CNY distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund (004685) held 1.6367 million shares, an increase of 129,400 shares from the previous period [3] - Nu'an Multi-Strategy Mixed A Fund (320016) entered as a new shareholder, holding 1.3943 million shares [3]

Investment Rating - The report maintains an investment rating of "Outperform" for the pharmaceutical and biotechnology industry, indicating a positive outlook compared to the broader market [4]. Core Insights - The pharmaceutical and biotechnology industry is experiencing a recovery in Q2 2025, with innovative drugs poised for significant development opportunities [1][10]. - The overall revenue for 461 A-share pharmaceutical companies in H1 2025 was CNY 11,939.5 billion, a year-on-year decrease of 3.21%, while net profit attributable to shareholders was CNY 1,016.2 billion, down 8.55% [8][24]. - The medical services sector showed positive growth, with revenue increasing by 3.92% year-on-year, while other segments like raw materials, chemical preparations, traditional Chinese medicine, and medical devices faced declines [8][24]. Summary by Sections 1. Market Review - The pharmaceutical and biotechnology index rose by 7.36% in H1 2025, outperforming the CSI 300 index by 7.33 percentage points, with the chemical preparation sector leading with a 20.09% increase [15][21]. 2. Industry Performance - In H1 2025, the chemical preparation sector reported a revenue of CNY 2,044.3 billion, down 5.77%, and a net profit of CNY 223.1 billion, down 22.92% [43]. - The medical services sector achieved a revenue of CNY 890.2 billion, with a significant net profit increase of 40.22% [8][24]. - The report highlights a trend of improving performance in Q2 compared to Q1, with several sectors showing signs of recovery [30]. 3. Subsector Analysis Raw Materials - The raw materials sector generated CNY 459.1 billion in revenue, a decrease of 6.74%, with a net profit of CNY 45.4 billion, down 2.71% [32][38]. - The report suggests a long-term growth outlook for the raw materials sector, driven by increasing demand and regulatory changes [38]. Chemical Preparations - The chemical preparations sector is expected to benefit from new policies supporting innovative drugs, with a focus on balancing price and clinical needs [48][49]. - The sector's revenue and profit are under pressure but are anticipated to recover as innovation and reform take hold [43][48]. Traditional Chinese Medicine - The traditional Chinese medicine sector reported a revenue of CNY 1,731.95 billion, with a slight profit increase of 0.24% [52]. - The sector is seen as having structural opportunities despite overall revenue declines [52]. Medical Services - The medical services sector is highlighted for its robust growth, with a focus on integrated service platforms [30][31]. Medical Devices - The medical devices sector is expected to recover as demand for equipment updates increases, with a revenue of CNY 1,155.6 billion, down 4.47% [8][30]. 4. Recommendations - The report recommends focusing on leading companies in various sectors, such as Tianyu Co. in raw materials, BeiGene in innovative drugs, and Yifeng Pharmacy in medical commerce [8][42][50].